A static-cidal assay for Trypanosoma brucei to aid hit prioritisation for progression into drug discovery programmes

Manu De Rycker (Lead / Corresponding author), Sandra O'Neill, Dhananjay Joshi, Lorna Campbell, David W. Gray, Alan H. Fairlamb

    Research output: Contribution to journalArticle

    20 Citations (Scopus)

    Abstract

    Human African Trypanosomiasis is a vector-borne disease of sub-Saharan Africa that causes significant morbidity and mortality. Current therapies have many drawbacks, and there is an urgent need for new, better medicines. Ideally such new treatments should be fast-acting cidal agents that cure the disease in as few doses as possible. Screening assays used for hit-discovery campaigns often do not distinguish cytocidal from cytostatic compounds and further detailed follow-up experiments are required. Such studies usually do not have the throughput required to test the large numbers of hits produced in a primary high-throughput screen. Here, we present a 384-well assay that is compatible with high-throughput screening and provides an initial indication of the cidal nature of a compound. The assay produces growth curves at ten compound concentrations by assessing trypanosome counts at 4, 24 and 48 hours after compound addition. A reduction in trypanosome counts over time is used as a marker for cidal activity. The lowest concentration at which cell killing is seen is a quantitative measure for the cidal activity of the compound. We show that the assay can identify compounds that have trypanostatic activity rather than cidal activity, and importantly, that results from primary high-throughput assays can overestimate the potency of compounds significantly. This is due to biphasic growth inhibition, which remains hidden at low starting cell densities and is revealed in our static-cidal assay. The assay presented here provides an important tool to follow-up hits from high-throughput screening campaigns and avoid progression of compounds that have poor prospects due to lack of cidal activity or overestimated potency.
    Original languageEnglish
    Pages (from-to)e1932
    JournalPLoS Neglected Tropical Diseases
    Volume6
    Issue number11
    DOIs
    Publication statusPublished - 29 Nov 2012

    Fingerprint

    Trypanosoma brucei brucei
    Trypanosomiasis
    Drug Discovery
    African Trypanosomiasis
    Disease Vectors
    Africa South of the Sahara
    Cytostatic Agents
    Growth
    Cell Count
    Morbidity
    Mortality
    Therapeutics

    Cite this

    @article{1aa57321e3f54b86a5dad71bf9290ad2,
    title = "A static-cidal assay for Trypanosoma brucei to aid hit prioritisation for progression into drug discovery programmes",
    abstract = "Human African Trypanosomiasis is a vector-borne disease of sub-Saharan Africa that causes significant morbidity and mortality. Current therapies have many drawbacks, and there is an urgent need for new, better medicines. Ideally such new treatments should be fast-acting cidal agents that cure the disease in as few doses as possible. Screening assays used for hit-discovery campaigns often do not distinguish cytocidal from cytostatic compounds and further detailed follow-up experiments are required. Such studies usually do not have the throughput required to test the large numbers of hits produced in a primary high-throughput screen. Here, we present a 384-well assay that is compatible with high-throughput screening and provides an initial indication of the cidal nature of a compound. The assay produces growth curves at ten compound concentrations by assessing trypanosome counts at 4, 24 and 48 hours after compound addition. A reduction in trypanosome counts over time is used as a marker for cidal activity. The lowest concentration at which cell killing is seen is a quantitative measure for the cidal activity of the compound. We show that the assay can identify compounds that have trypanostatic activity rather than cidal activity, and importantly, that results from primary high-throughput assays can overestimate the potency of compounds significantly. This is due to biphasic growth inhibition, which remains hidden at low starting cell densities and is revealed in our static-cidal assay. The assay presented here provides an important tool to follow-up hits from high-throughput screening campaigns and avoid progression of compounds that have poor prospects due to lack of cidal activity or overestimated potency.",
    author = "{De Rycker}, Manu and Sandra O'Neill and Dhananjay Joshi and Lorna Campbell and Gray, {David W.} and Fairlamb, {Alan H.}",
    year = "2012",
    month = "11",
    day = "29",
    doi = "10.1371/journal.pntd.0001932",
    language = "English",
    volume = "6",
    pages = "e1932",
    journal = "PLoS Neglected Tropical Diseases",
    issn = "1935-2727",
    publisher = "Public Library of Science",
    number = "11",

    }

    TY - JOUR

    T1 - A static-cidal assay for Trypanosoma brucei to aid hit prioritisation for progression into drug discovery programmes

    AU - De Rycker, Manu

    AU - O'Neill, Sandra

    AU - Joshi, Dhananjay

    AU - Campbell, Lorna

    AU - Gray, David W.

    AU - Fairlamb, Alan H.

    PY - 2012/11/29

    Y1 - 2012/11/29

    N2 - Human African Trypanosomiasis is a vector-borne disease of sub-Saharan Africa that causes significant morbidity and mortality. Current therapies have many drawbacks, and there is an urgent need for new, better medicines. Ideally such new treatments should be fast-acting cidal agents that cure the disease in as few doses as possible. Screening assays used for hit-discovery campaigns often do not distinguish cytocidal from cytostatic compounds and further detailed follow-up experiments are required. Such studies usually do not have the throughput required to test the large numbers of hits produced in a primary high-throughput screen. Here, we present a 384-well assay that is compatible with high-throughput screening and provides an initial indication of the cidal nature of a compound. The assay produces growth curves at ten compound concentrations by assessing trypanosome counts at 4, 24 and 48 hours after compound addition. A reduction in trypanosome counts over time is used as a marker for cidal activity. The lowest concentration at which cell killing is seen is a quantitative measure for the cidal activity of the compound. We show that the assay can identify compounds that have trypanostatic activity rather than cidal activity, and importantly, that results from primary high-throughput assays can overestimate the potency of compounds significantly. This is due to biphasic growth inhibition, which remains hidden at low starting cell densities and is revealed in our static-cidal assay. The assay presented here provides an important tool to follow-up hits from high-throughput screening campaigns and avoid progression of compounds that have poor prospects due to lack of cidal activity or overestimated potency.

    AB - Human African Trypanosomiasis is a vector-borne disease of sub-Saharan Africa that causes significant morbidity and mortality. Current therapies have many drawbacks, and there is an urgent need for new, better medicines. Ideally such new treatments should be fast-acting cidal agents that cure the disease in as few doses as possible. Screening assays used for hit-discovery campaigns often do not distinguish cytocidal from cytostatic compounds and further detailed follow-up experiments are required. Such studies usually do not have the throughput required to test the large numbers of hits produced in a primary high-throughput screen. Here, we present a 384-well assay that is compatible with high-throughput screening and provides an initial indication of the cidal nature of a compound. The assay produces growth curves at ten compound concentrations by assessing trypanosome counts at 4, 24 and 48 hours after compound addition. A reduction in trypanosome counts over time is used as a marker for cidal activity. The lowest concentration at which cell killing is seen is a quantitative measure for the cidal activity of the compound. We show that the assay can identify compounds that have trypanostatic activity rather than cidal activity, and importantly, that results from primary high-throughput assays can overestimate the potency of compounds significantly. This is due to biphasic growth inhibition, which remains hidden at low starting cell densities and is revealed in our static-cidal assay. The assay presented here provides an important tool to follow-up hits from high-throughput screening campaigns and avoid progression of compounds that have poor prospects due to lack of cidal activity or overestimated potency.

    U2 - 10.1371/journal.pntd.0001932

    DO - 10.1371/journal.pntd.0001932

    M3 - Article

    C2 - 23209868

    VL - 6

    SP - e1932

    JO - PLoS Neglected Tropical Diseases

    JF - PLoS Neglected Tropical Diseases

    SN - 1935-2727

    IS - 11

    ER -